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For example,  the  ‘nano’  label  is used  to qualify practices where  the definition, 














This  article  challenges  the  idea  that  bioethical  statements  are  elements of  a 
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Ethical Stakes: External Judgements or Industrial Activities-based-statements?



























applied  to objects, nor a collection of  reasoning processes  that are  isolated  from 
the rest of industrial activities. Various elements which came out of the interviews 






































of our  research. We communicate almost  exclusively on  the products which 
move  into clinical use  […] There,  that’s  something we are asking ourselves 
these days—should we not communicate earlier concerning our programmes? 
[…] There  is  a  dimension which  involves  the  scientific  community  and  the 
community at large.’9
These notions are also found in the context of consent: 


















































































Producing Ethics Within the Companies: A Variability of Text References and 
Arenas ‘Without Borders’
The references mentioned as being ‘sources for ethics’ are very variable (Memmi, 
1996,  pp.  1–254),  ranging  from binding  legal  instruments  (laws,  directives)  to 
professional  recommendations (FDA, Guidelines, Charters,  the bioethics group 
of Europabio, etc.).  It  should be noted  that only  two companies  spontaneously 
mentioned ethical recommendations as being a source on which they could rely. 























































































The ‘wide diversity of biological samples’ stored is another important factor that 
interferes with the production of bioethical norms. Actually, there is a lot of tension 
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By extension,  ‘quality control  for an  innovative  treatment’ product acquires 
a strong ethical connotation when it is difficult to obtain, or if its properties are 
donor-dependent. So, when it has been made from lines of embryonic stem cells 








in  the  translational  line  from bench  to bedside. For  those who  intervene at  the 
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(or  of  culture,  for  human  cells):  ‘[…] This  score which gives  us  a fingerprint 
of  the phenotypic stability  […]  I  think  for us,  it’s mainly  the ethical questions 
about who is the owner of the material, and can we refuse a patient if the quality 
is not optimal’.26
So,  the  production  of  ethics  is  strongly  related  to  the  quality  control  and 






























Means of Resolving Ethical Questions by Resorting to Agencies:  















































































For  biotech  actors,  regulation  by  law  is  both  envisaged  as  a  constraint  and  a 
liberating element. This regulation seems to be desired in order to establish stable 
guidelines:
In many  countries,  as  in  Sweden,  Finland, Denmark,  France, Belgium,  the 


































pp. 205–226)  for producing ethics  in  the company with  regard  to  its particular 



































































(academics,  patient  associations, manufacturers) who have got  together  over  a 




















Infrastructure Stability and Ethical Production
Uncertainty, new social arrangements Path dependency, routines, guidelines
Shared accountability
Reduction of bioethical concerns
Unstable Stable infrastructure-agency

















an  analysis  of  emerging  industrial  activities  can  lead  to  explore  the  horizontal 
dimension of  collective  experiences. Bioethics  can be  seen  as  a  specific  form 







  1.  This  expression  refers  to  its  use  in  anthropology  and  emphasises  artefacts  as  a  subject  unto 
themselves. It does not echoe the technical aspect of ‘cell culture’ or ‘biological material’ used 
elsewhere in the fieldwork. 
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